Evidence map›Paper›PMID 42905934›Full record

ArticleAmerican journal of reproductive immunology (New York, N.Y. : 1989)2026

Genital Tract and Circulating CD8+ T Cell Phenotypes Vary Across the Menstrual Cycle.

Irene Cruz Talavera, Katherine K Thomas, Jessica B Graham, Jessica L Swarts, Sarah C Vick, Finn MacLean, Nicole B Potchen, Lakshmi Warrier, Adino Tesfahun Tsegaye, Sean M Hughes and 7 more

Abstract read
In one paragraph

Article in American journal of reproductive immunology (New York, N.Y. : 1989), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Irene Cruz TalaveraVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-0500-3038
Katherine K ThomasDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-7024-468X
Jessica B GrahamVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-6579-0443
Jessica L SwartsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Sarah C VickVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-0552-0078
Finn MacLeanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0009-0009-4100-1302
Nicole B PotchenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-0699-8863
Lakshmi WarrierVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-2413-0761
Adino Tesfahun TsegayeDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Sean M HughesDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-9409-9405
Florian HladikVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Bhavna H ChohanDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-2125-6799
Kenneth NgureDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-8062-0933
Nelly MugoDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-2347-006X
Jairam R Lingappa *Department of Global Health, University of Washington, Seattle, Washington, USA.
Jennifer M Lund *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-3284-979X
Kinga Study Team

Funding

VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Identification of Novel Mucosal Immune Mechanisms Involved in Protection from HIV-1R01AI131914 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LINGAPPA, JAIRAM RAO, LUND, JENNIFER M · 2017 to 2021
$4.0M
T-cell activation and exhaustion in the HIV-positive female genital tractR01HD114505 · NICHD · UNIVERSITY OF WASHINGTON · PI Jennifer M Lund, Raymond Scott McClelland · 2023 to 2026
$3.9M
Tissue Regulatory T Cells in Mucosal InfectionR01AI141435 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LUND, JENNIFER M · 2019 to 2023
$3.2M
Viral Pathogenesis Training ProgramT32AI083203 · NIAID · UNIVERSITY OF WASHINGTON · PI BLOOM, JESSE D, LAGUNOFF, MICHAEL · 2009 to 2023
$2.7M
NIH HHS AI129715NIH HHS R01 AI131914NIH HHS R01 AI141435NIH HHS R01 HD114505NIH HHS T32AI007140NIH HHS T32AI007509NIH HHS T32AI083203
6 · The paper itself

Abstract

problemThe menstrual cycle consists of two main phases: the follicular phase, characterized by rising estradiol and low progesterone, and the luteal phase, marked by elevated progesterone following ovulation. Changes in sex hormones have profound physiological effects, yet their impact on immunity remains poorly understood. The prevailing theory suggests that reduced immunity during the luteal phase facilitates embryo implantation but also increases susceptibility to infections. Thus, defining the impact of the menstrual cycle on genital and systemic immunity is critical to understanding how immunity at different sites may be affected. METHOD OF STUDY: We examined phenotypic differences in T cells from ectocervical and vaginal tissue biopsies and blood samples collected from 58 women in the follicular phase and 20 women in the luteal phase using flow cytometry and measured seventy-one cytokines and chemokines from serum and cervicovaginal secretions.

resultsThe proportions of CD8+ memory T cell subsets varied with menstrual phase, with a higher frequency of central memory cells during the luteal phase and more TEMRA cells during the follicular phase. Cervical CD8+ T cells exhibited higher frequencies of CD38 and CD39 during the luteal phase. We found higher CCL15 and IL-2 concentrations in cervicovaginal fluid, and higher CXCL12 in serum, during the follicular phase. During the luteal phase, CXCL13 was higher in cervicovaginal secretions.

conclusionsOur findings provide insight into how menstrual phase modulates genital CD8+ T cell phenotypes and memory subsets throughout the cycle and may influence immunity in distinct tissue compartments with consequences for local infection vulnerability.

Indexed as

CD8-Positive T-LymphocytesCervix UteriLuteal PhaseMemory T CellsMenstrual CycleVaginaAdultCytokinesFemaleFollicular PhaseHumansImmunologic MemoryPhenotypeYoung AdultCytokinescytokinesfollicular phasegenital tract immunityluteal phasemenstrual cycleT cells

Identifiers

PMID42905934
PMCPMC13686575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.